J B Hunt Transport Services Inc vs ResMed Inc. — how do they compare? J B Hunt Transport Services Inc trades at $229 (market cap $21.45B), while ResMed Inc. trades at $225.92 (market cap $31.89B). The key difference: ResMed Inc. is the larger of the two by market cap, and ResMed Inc. pays the higher dividend (1.16%). Which is the better fit depends on your goals — on Pluang, investors hold J B Hunt Transport Services Inc for 45 Days and ResMed Inc. for 51 Days on average.
| JBHT | RMD | |
|---|---|---|
Market Cap | $21.45B | $31.89B |
Volume | 1,028,680 | 618,314 |
Sector | Industrials | Health |
52-Week High | $298.41 | $277.88 |
52-Week Low | $137.09 | $182.82 |
Typical Hold Time | 45 Days | 51 Days |
Enterprise Value | $22.59B | $31.24B |
Dividend Yield | 0.79% | 1.16% |
Signals from Pluang's Aura AI — not financial advice
JBHT trades at $222.64, down 1.46% on the day, amid a bearish technical signal and ongoing securities class action investigations. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected October 15, 2026. Fundamentals show a P/E of 31.67, net income margin of 5.31%, and strong cash flow from operations of $1.68 billion in 2025. Analyst consensus remains bullish with a $289.40 price target, though rising costs and legal scrutiny present headwinds.
The outlook is mixed; strong freight demand and earnings beats support upside potential, but near-term pressure from fuel costs and legal overhangs may limit gains. The stock offers value if operational efficiency improves, yet investors face risks from volatile diesel prices and potential litigation outcomes. The upcoming Q3 earnings will be critical for confirming the company's ability to navigate cost pressures.
ResMed (RMD) trades at $225.98, up 2.4% today, with a bullish technical signal and strong fundamentals. Revenue grew to $5.15B in 2025, with net income at $1.40B and a 26.94% net margin. Recent earnings beats and a 12-14% EPS growth outlook support momentum. The stock is near its pivot point of $227, with support at $225 and resistance at $228.
Outlook is positive with analyst consensus at Buy and a $242.70 price target. Risks include competitive pressures and ongoing legal investigations. Institutional buying and solid cash flow growth underpin the bullish case, though macroeconomic and regulatory factors warrant monitoring.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
J.B. Hunt Transport Services ranks among the top surface transportation companies in North America by revenue. Its primary operating segments are intermodal delivery, which uses the Class I rail carriers for the underlying line-haul movement of its owned containers (45% of sales in 2021).
Read more on JBHT →ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →